Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice.

Autor: Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC

Publikováno v: Cancer cell [Cancer Cell] 2024 Jun 10; Vol. 42 (6), pp. 1127. Date of Electronic Publication: 2024 May 30.

CAVPENET Peptide Inhibits Prostate Cancer Cells Proliferation and Migration through PP1γ-Dependent Inhibition of AKT Signaling.

Autor: Matos, Bárbara^1,2 (AUTHOR) barbaracostamatos@ua.pt, Gomes, Antoniel A. S.³ (AUTHOR) antoniel.gomes@unesp.br, Bernardino, Raquel^4,5 (AUTHOR) raquellbernardino@gmail.com, Alves, Marco G.⁶ (AUTHOR) marcoalves@ua.pt, Howl, John⁷ (AUTHOR) john.howl@bcu.ac.uk, Jerónimo, Carmen^2,8 (AUTHOR), Fardilha, Margarida¹ (AUTHOR) mfardilha@ua.pt

Publikováno v: Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1199. 26p.

A roadmap for clinical trials in MASH-related compensated cirrhosis.

Autor: Pericàs JM; Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain. juanmanuel.pericas@vallhebron.cat.; Centros de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. juanmanuel.pericas@vallhebron.cat., Anstee QM; Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.; Newcastle NIHR Biomedical Research Center, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK., Augustin S; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Bataller R; Liver Unit, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat Barcelona, Barcelona, Spain., Berzigotti A; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Ciudin A; Endocrinology and Nutrition Department, Morbid Obesity Unit Coordinator, Vall d'Hebron University Hospital, Barcelona, Spain.; Centros de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas asociadas (CIBERdem), Instituto de Salud Carlos III, Madrid, Spain., Francque S; Department of Gastroenterology and Hepatology, Antwerp University Hospital, InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium., Abraldes JG; Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Canada., Hernández-Gea V; Centros de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.; Liver Unit, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat Barcelona, Barcelona, Spain., Pons M; Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain., Reiberger T; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria., Rowe IA; Leeds Institute for Medical Research, University of Leeds, Leeds, UK., Rydqvist P; Medical Department, Madrigal Pharmaceuticals, West Conshohocken, PA, USA., Schabel E; Federal Institute for Drugs and Medical Devices, Bonn, Germany., Tacke F; Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Tsochatzis EA; UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK., Genescà J; Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.; Centros de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.

Publikováno v: Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol] 2024 Nov; Vol. 21 (11), pp. 809-823. Date of Electronic Publication: 2024 Jul 17.

Predictive factors of portal hypertensive enteropathy exacerbations based on long-term outcomes.

Autor: Matsubara, Yuka¹ (AUTHOR), Tsuboi, Akiyoshi^1,2 (AUTHOR) atsuboi@hiroshima-u.ac.jp, Hirata, Issei¹ (AUTHOR), Sumioka, Akihiko¹ (AUTHOR), Takasago, Takeshi¹ (AUTHOR), Tanaka, Hidenori¹ (AUTHOR), Yamashita, Ken¹ (AUTHOR), Hiyama, Yuichi¹ (AUTHOR), Takigawa, Hidehiko¹ (AUTHOR), Murakami, Eisuke¹ (AUTHOR), Tsuge, Masataka¹ (AUTHOR), Urabe, Yuji¹ (AUTHOR), Oka, Shiro¹ (AUTHOR)

Publikováno v: BMC Gastroenterology. 8/26/2024, Vol. 24 Issue 1, p1-10. 10p.

Feasibility and safety of ultrasound-guided percutaneous transhepatic measurement of portal venous pressure.

Autor: Hu, Yanshan^1,2 (AUTHOR), Duan, Shaobo^1,2,3 (AUTHOR), Zhang, Ye³ (AUTHOR), Hao, Liuwei³ (AUTHOR), Wang, Shuaiyang³ (AUTHOR), Xue, Fei⁴ (AUTHOR), Zhang, Kewei⁵ (AUTHOR), Zhu, Yadong⁵ (AUTHOR), Zhang, Lianzhong^1,2,6 (AUTHOR) zlz8777@163.com

Publikováno v: PLoS ONE. 7/19/2024, Vol. 19 Issue 7, p1-14. 14p.